Unveiling efferocytosis-related signatures through the integration of single-cell analysis and machine learning: a predictive framework for prognosis and immunotherapy response in hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) represents a prominent gastrointestinal malignancy with a grim clinical outlook. In this regard, the discovery of novel early biomarkers holds substantial promise for ameliorating HCC-associated mortality. Efferocytosis, a vital immunological process, assumes a central position in the elimination of apoptotic cells. However, comprehensive investigations exploring the role of efferocytosis-related genes (EFRGs) in HCC are sparse, and their regulatory influence on HCC immunotherapy and targeted drug interventions remain poorly understood. Methods RNA sequencing data and clinical characteristics of HCC patients were acquired from the TCGA database. To identify prognostically significant genes in HCC, we performed the limma package and conducted univariate Cox regression analysis. Subsequently, machine learning algorithms were employed to identify hub genes. To assess the immunological landscape of different HCC subtypes, we employed the CIBERSORT algorithm. Furthermore, single-cell RNA sequencing (scRNA-seq) was utilized to investigate the expression levels of ERFGs in immune cells and to explore intercellular communication within HCC tissues. The migratory capacity of HCC cells was evaluated using CCK-8 assays, while drug sensitivity prediction reliability was determined through wound-healing assays. Results We have successfully identified a set of nine genes, termed EFRGs, that hold significant potential for the establishment of a hepatocellular carcinoma-specific prognostic model. Furthermore, leveraging the individual risk scores derived from this model, we were able to stratify patients into two distinct risk groups, unveiling notable disparities in terms of immune infiltration patterns and response to immunotherapy. Notably, the model’s capacity to accurately predict drug responses was substantiated through comprehensive experimental investigations, encompassing wound-healing assay, and CCK8 experiments conducted on the HepG2 and Huh7 cell lines. Conclusions We constructed an EFRGs model that serves as valuable tools for prognostic assessment and decision-making support in the context of immunotherapy and chemotherapy.

[1]  Guobin Song,et al.  CD8 + T-cell marker genes reveal different immune subtypes of oral lichen planus by integrating single-cell RNA-seq and bulk RNA-sequencing , 2023, BMC Oral Health.

[2]  J. Zhang,et al.  Revolutionizing anti-tumor therapy: unleashing the potential of B cell-derived exosomes , 2023, Frontiers in Immunology.

[3]  Pengpeng Zhang,et al.  A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts , 2023, Frontiers in Immunology.

[4]  Qin Wang,et al.  FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC , 2023, Frontiers in Molecular Biosciences.

[5]  Leilei Wu,et al.  Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma , 2023, Frontiers in Endocrinology.

[6]  G. Du,et al.  HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma , 2023, Biomarker Research.

[7]  Shiyi Sun,et al.  Integrating single-cell analysis and machine learning to create glycosylation-based gene signature for prognostic prediction of uveal melanoma , 2023, Frontiers in Endocrinology.

[8]  Hao Jiang,et al.  Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma , 2023, Frontiers in Immunology.

[9]  Jinhui Liu,et al.  Circadian rhythm-related genes index: A predictor for HNSCC prognosis, immunotherapy efficacy, and chemosensitivity , 2023, Frontiers in Immunology.

[10]  S. Frye,et al.  Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment , 2023, Frontiers in Immunology.

[11]  F. Gao,et al.  Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer , 2023, Frontiers in Endocrinology.

[12]  N. Hayward,et al.  Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy. , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Ke Su,et al.  Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson’s disease , 2023, Frontiers in Immunology.

[14]  M. Hung,et al.  Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma. , 2023, Gastroenterology.

[15]  Hengyu Li,et al.  M6A-mediated upregulation of FZD10 regulates liver cancer stem cells properties and lenvatinib resistance through WNT/β-catenin and Hippo signaling pathways. , 2023, Gastroenterology.

[16]  F. Greten,et al.  Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade , 2023, Gut.

[17]  A. Teichmann,et al.  Exosomes: A potential tool for immunotherapy of ovarian cancer , 2023, Frontiers in Immunology.

[18]  Yufeng Liu,et al.  Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. , 2023, Journal of hepatology.

[19]  A. Bazhin,et al.  NOP2-mediated m5C Modification of c-Myc in an EIF3A-Dependent Manner to Reprogram Glucose Metabolism and Promote Hepatocellular Carcinoma Progression , 2023, Research.

[20]  K. Keshari,et al.  Metabolic adaptation supports enhanced macrophage efferocytosis in limited-oxygen environments. , 2022, Cell metabolism.

[21]  Xiaosong Li,et al.  Ensemble deep learning enhanced with self-attention for predicting immunotherapeutic responses to cancers , 2022, Frontiers in Immunology.

[22]  G. Du,et al.  LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance , 2022, Genes & diseases.

[23]  Xiaosong Li,et al.  IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines? , 2022, Frontiers in Immunology.

[24]  Wenyi Jin,et al.  Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature , 2022, Frontiers in Endocrinology.

[25]  Gang Tian,et al.  Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC , 2022, Frontiers in Immunology.

[26]  Suhyuk Lee,et al.  Emerging roles of neutrophils in immune homeostasis , 2022, BMB reports.

[27]  Xiaomei Zhou,et al.  Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer , 2022, Frontiers in Immunology.

[28]  Cong Yu,et al.  The prognostic value of MicroRNAs associated with fatty acid metabolism in head and neck squamous cell carcinoma , 2022, Frontiers in Genetics.

[29]  Yue Zhao,et al.  A novel anoikis-related gene signature predicts prognosis in patients with head and neck squamous cell carcinoma and reveals immune infiltration , 2022, Frontiers in Genetics.

[30]  Wenyi Jin,et al.  A novel inflammation-associated prognostic signature for clear cell renal cell carcinoma , 2022, Oncology letters.

[31]  V. Bonato,et al.  RIP2 Contributes to Expanded CD4+ T Cell IFN-γ Production during Efferocytosis of Streptococcus pneumoniae–Infected Apoptotic Cells , 2022, ImmunoHorizons.

[32]  K. Ravichandran,et al.  Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes , 2022, Nature.

[33]  Longqing Tang,et al.  Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. , 2022, Cancer immunology research.

[34]  M. Yan,et al.  Interaction between macrophages and ferroptosis , 2022, Cell Death & Disease.

[35]  Meixiao Zhan,et al.  PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma , 2022, Gut.

[36]  Jian Zhu,et al.  MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression , 2022, Oncoimmunology.

[37]  Fan Zhang,et al.  LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b , 2022, Molecular Medicine.

[38]  E. García-Pras,et al.  Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities , 2021, Cancers.

[39]  A. Dohan,et al.  Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma? , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[40]  V. Mazzaferro,et al.  Immunotherapies for hepatocellular carcinoma , 2021, Nature Reviews Clinical Oncology.

[41]  A. Bazhin,et al.  The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies , 2021, Frontiers in Oncology.

[42]  Yong Teng,et al.  The complex roles of efferocytosis in cancer development, metastasis, and treatment. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[43]  Darjus F. Tschaharganeh,et al.  Liver Inflammation and Hepatobiliary Cancers. , 2021, Trends in cancer.

[44]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[45]  I. Hardardottir,et al.  Docosahexaenoic Acid Modulates NK Cell Effects on Neutrophils and Their Crosstalk , 2020, Frontiers in Immunology.

[46]  Taicheng Zhou,et al.  A Novel Ten-Gene Signature Predicting Prognosis in Hepatocellular Carcinoma , 2020, Frontiers in Cell and Developmental Biology.

[47]  Dianpeng Li,et al.  Mogroside IIE Inhibits Digestive Enzymes via Suppression of Interleukin 9/Interleukin 9 Receptor Signalling in Acute Pancreatitis , 2020, Frontiers in Pharmacology.

[48]  Hao Peng,et al.  Exploration of the molecular characteristics of the tumor–immune interaction and the development of an individualized immune prognostic signature for neuroblastoma , 2020, Journal of cellular physiology.

[49]  Z. Modrušan,et al.  Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. , 2020, Immunity.

[50]  John A. Bohlin,et al.  Statistical predictions with glmnet , 2019, Clinical Epigenetics.

[51]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[52]  Junfei Jin,et al.  Decreased S1P and SPHK2 are involved in pancreatic acinar cell injury. , 2019, Biomarkers in medicine.

[53]  K. Pienta,et al.  Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment , 2019, Molecular Cancer.

[54]  K. Ravichandran,et al.  Living on the Edge: Efferocytosis at the Interface of Homeostasis and Pathology. , 2019, Immunity.

[55]  C. Li,et al.  Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China , 2019, JAMA surgery.

[56]  E. Seki,et al.  Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets , 2019, Seminars in Liver Disease.

[57]  K. Kodys,et al.  Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use. , 2018, Journal of hepatology.

[58]  T. Werfel,et al.  Efferocytosis in the tumor microenvironment , 2018, Seminars in Immunopathology.

[59]  Zhongguo Zhou,et al.  Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma , 2018, British Journal of Cancer.

[60]  K. Odunsi,et al.  The CD47 "don't eat me signal" is highly expressed in human ovarian cancer. , 2016, Gynecologic Oncology.

[61]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[62]  R. Cook,et al.  Efferocytosis creates a tumor microenvironment supportive of tumor survival and metastasis. , 2015, Cancer cell & microenvironment.

[63]  K. Davies,et al.  The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.

[64]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[65]  K. Pienta,et al.  Polarization of Prostate Cancer-associated Macrophages Is Induced by Milk Fat Globule-EGF Factor 8 (MFG-E8)-mediated Efferocytosis* , 2014, The Journal of Biological Chemistry.

[66]  Adriano G. Rossi,et al.  Apoptotic cell clearance: basic biology and therapeutic potential , 2014, Nature Reviews Immunology.

[67]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[68]  H. Banerjee,et al.  Efferocytosis and the Story of "Find Me," "Eat Me," and "Don't Eat Me" Signaling in the Tumor Microenvironment. , 2021, Advances in experimental medicine and biology.

[69]  Jean Claude Zenklusen,et al.  A Practical Guide to The Cancer Genome Atlas (TCGA) , 2016, Statistical Genomics.